Traders Buy Shares of Pfizer (PFE) on Weakness After Insider Selling

Investors bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Wednesday following insider selling activity. $151.04 million flowed into the stock on the tick-up and $65.02 million flowed out of the stock on the tick-down, for a money net flow of $86.02 million into the stock. Of all stocks tracked, Pfizer had the 8th highest net in-flow for the day. Pfizer traded down ($0.07) for the day and closed at $42.84Specifically, insider Rady A. Johnson sold 8,700 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $41.13, for a total transaction of $357,831.00. Following the sale, the insider now directly owns 59,797 shares in the company, valued at approximately $2,459,450.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mikael Dolsten sold 100,471 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $43.56, for a total transaction of $4,376,516.76. Following the sale, the insider now owns 390,097 shares in the company, valued at $16,992,625.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 332,526 shares of company stock worth $14,346,539. Corporate insiders own 0.09% of the company’s stock.

A number of analysts recently commented on the stock. Cantor Fitzgerald set a $53.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Sunday, December 30th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Thursday, January 31st. JPMorgan Chase & Co. cut shares of Pfizer from an “overweight” rating to a “neutral” rating and set a $46.00 price target on the stock. in a research note on Tuesday, December 11th. Zacks Investment Research cut shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Finally, Credit Suisse Group restated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, January 28th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $45.16.

The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.33 and a current ratio of 1.57. The firm has a market capitalization of $255.44 billion, a price-to-earnings ratio of 14.28, a P/E/G ratio of 2.45 and a beta of 0.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The business had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. Pfizer had a net margin of 20.79% and a return on equity of 26.02%. Pfizer’s revenue was up 2.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 EPS. Equities analysts predict that Pfizer Inc. will post 2.86 earnings per share for the current year.

Pfizer declared that its Board of Directors has approved a share buyback program on Friday, December 14th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 3.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Several large investors have recently modified their holdings of PFE. Advocacy Wealth Management Services LLC grew its holdings in shares of Pfizer by 48.2% during the 4th quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 258 shares during the last quarter. Winch Advisory Services LLC grew its holdings in shares of Pfizer by 69.6% during the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 336 shares during the last quarter. 1 North Wealth Services LLC purchased a new stake in Pfizer during the 4th quarter valued at $40,000. Ruggie Capital Group purchased a new stake in Pfizer during the 4th quarter valued at $44,000. Finally, Contravisory Investment Management Inc. boosted its position in Pfizer by 182.6% during the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 745 shares during the period. 69.53% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Traders Buy Shares of Pfizer (PFE) on Weakness After Insider Selling” was posted by Stock Observer and is owned by of Stock Observer. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.thestockobserver.com/2019/04/04/traders-buy-shares-of-pfizer-pfe-on-weakness-after-insider-selling.html.

Pfizer Company Profile (NYSE:PFE)

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: How Do Front-End Loads Impact an Investment?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.